LSP Medicine Store Licensing & Compliance

An LSP is a retail qualification for Part II poisons that is restricted to specified premises. It is not a “small pharmacy” or a general licence for any Western medicine business. Project planning should first establish whether the business involves LSP retail, rather than an ASP pharmacy, wholesale, manufacture, antibiotics, dangerous drugs or Chinese medicine business.

[Statutory requirements] An LSP under section 25 of Cap. 138 is a person whose name is entered in the Board’s register and who may sell by retail poisons specified in Part II of the Poisons List. The application must be made by the occupier of the premises proposed for use, and the approved licence specifies the categories that may be sold. Section 26 further provides that Part II poisons may only be sold by an ASP at registered premises or by an LSP. The licence is therefore not an asset that can circulate freely, independently of the holder and designated premises.

[Official Code requirements] An LSP may sell Part II poisons by retail only at the premises specified in its licence. The premises must not be used to possess or sell antibiotics, Part I poisons or dangerous drugs, or to dispense any prescription for a pharmaceutical product. If the business plan involves wholesale, import/export, manufacture, antibiotics or dangerous drugs, check the relevant permissions separately according to the actual activities. Do not interpret the LSP licence as authorising these activities.

[Risk alert] “Pharmacy”, “pharmacist supervision”, “prescription services” and ℞ are not marketing terms that a medicine shop may borrow. The shop name, sign, display windows, website, social media, staff communications and partner pages should all be consistent with LSP status. Even if someone with a relevant background is employed on the premises, this does not permit the LSP to promote itself as an ASP.

LSP compliance does not begin with marketing categories such as “cold medicine”, “pain relief” or “non-prescription”. It begins with checking each product against the applicable Poisons List, sales classification, labelling, registration and other legislation.

[Official classification] The Department of Health FAQ explains that pharmaceutical products containing no poisons and those containing Part II poisons may both be described as OTC, but the former may be sold in any retail shop, while the latter may only be sold by an ASP or LSP. Products containing Part I poisons may only be sold by an ASP with a registered pharmacist present and supervising. Part I poisons in Schedule 3 also require a prescription from a registered medical practitioner, dentist or veterinary surgeon. Therefore, “not a prescription medicine” does not automatically mean “may be sold by an LSP”.

[Verification method] The scope of Part II poisons is governed by the ingredient classifications in Schedule 10 to Cap. 138A and the relevant legal controls. The Department of Health’s introduction to the drug regulatory system gives cold and flu medicines, antipyretics and analgesics as illustrative examples of Category 3 products. The current LSP application guidelines also give cold and flu medicines containing paracetamol and chlorpheniramine, and hair dye preparations containing phenylenediamines and similar ingredients, as examples. These examples do not authorise all products in the same categories to be treated as within the scope of an LSP. Nor should dosage or efficacy conclusions be added without checking the specific ingredients, product form and labelling.

[Drew Tang’s practical recommendation] When setting up the SKU master file, retain for every product proposed for sale at least its brand and registration details, active ingredients and classification conclusion, permitted sales channels, supplier, batch number and expiry date. If the ingredients, packaging, registration status or classification information do not match, stop sales, quarantine the product and review it. Staff should not decide whether a product may be sold based on its intended use or a customer’s description.

[ASP Pharmacist Presence and the Boundaries for Controlled Medicines] An ASP must not merely arrange for a pharmacist to attend temporarily when sales take place. On each business day, a registered pharmacist must be physically present for no less than two-thirds of the ASP's opening hours and exercise control and supervision over employees. Controlled medicines may only be sold by a registered pharmacist or in the presence and under the supervision of one. Part 1 Schedule 3 poisons, antibiotics and dangerous drugs additionally require a prescription from a registered medical practitioner, dentist or veterinary surgeon, and may only be dispensed at registered premises by a registered pharmacist or in the presence and under the supervision of one. A pharmacist's absence does not permit these medicines to be supplied by an LSP, shop staff or a general retail outlet.

The application documents should provide a consistent chain of evidence linking the licence holder, occupation of the premises, management personnel and actual operating arrangements. A limited company may be used, but it is not the only available form.

[Official documents] The current LSP checklist accepts limited companies, sole proprietorships and partnerships. All applicants must provide Business Registration details. A limited company must attach its Certificate of Incorporation and list of directors; a sole proprietorship must attach Business Registration Form 1(a); and a partnership must attach Form 1(c). The statutory framework in section 25 of Cap. 138 also emphasises the relationship between the applicant and the proposed premises. Company information, Business Registration, tenancy agreement, shop name and application form should therefore be consistent with each other.

[Statutory and Code requirements] If the licence holder proposes to change the sole proprietor, partnership or directors, it must first obtain the Board’s approval. Otherwise, it may be removed from the register and the licence may become invalid from the date of removal. A filing with the Companies Registry or the entry into force of a shareholders’ agreement does not mean that approval has been obtained for LSP purposes. Section 25 of Cap. 138 also allows applications to amend register details; once approved by the Board, the prescribed amendment fee must be paid. Do not quote an amount before confirming the applicable form and fee at the time.

[Risk alert] The Code does not separately state that an ordinary shareholder change is automatically treated in exactly the same way as a change of director. A share transaction may nevertheless also change directors, signing authority, actual management, the person in charge or suitability information. Rather than treating “no change of directors means nothing needs to be done” as conclusive, prepare a comparison of changes to control, directors, authority and day-to-day management, then confirm the procedure for the case with the Drug Office.

Having a registered pharmacist on site is not an LSP application requirement, but the regulator will not look only at a letter of appointment. Declarations about the person in charge, proprietor / partner / director and Western medicine staff should reflect who actually controls the goods, premises, staff and compliance decisions.

[Official documents] The application form requires the name, position and contact details of the person in charge of the business. This person may be the proprietor, a partner, a director or another person specified in the form. The checklist requires the names in English and Chinese, Hong Kong Identity Card numbers and positions of the proprietor / partners / directors and all Western medicine staff. It also requires relevant persons to declare whether, in the past 3 years, they have been involved with another Western medicine trader, are under investigation or prosecution, or have a medicine-related conviction.

[Scope of available information] The LSP application form, checklist, application guidelines and Code of Practice verified here do not make it an application requirement that the person in charge be a registered pharmacist, hold a specific pharmacy qualification or pass a uniform LSP examination. Conversely, this does not mean that the person in charge may be a nominee only: the application guidelines consider the suitability of the applicant and key personnel, medicine-related convictions and disciplinary records, while the on-site inspection will also verify actual staffing and operating arrangements.

[Drew Tang’s practical recommendation] Define the person in charge’s duties in operational terms, including oversight of product classification, receipt checks, quarantine of expired and recalled goods, cooperation during regulatory visits, staff training and escalation of irregularities. Establish the same documentation and training records for backup personnel, but do not promote internal training or consultant guidance as a government-recognised qualification, or imply that Drew Tang or any business manager is a registered pharmacist.

An LSP’s sales location is not just a general correspondence address. The application, inspection, licence and actual retail activity must all be planned around the same approved premises.

[Official requirements] The current application guidelines state that, after receiving a complete application, the premises will be inspected for suitability for retailing Part II poisons. Residential addresses or units are generally considered unsuitable. The Code requires the premises to comply with the law, be properly maintained and be suitable for retailing Part II poisons or other pharmaceutical products. They must also be kept clean and tidy, with adequate lighting, ventilation and air-conditioning. Official information does not specify a uniform minimum floor area, so the layout plan should show actual workflows and control measures rather than pursue an unsupported area figure.

[Display requirements] The LSP name must be prominently displayed outside the premises. The LSP licence must be prominently displayed in the retail area so that the public can identify and inspect it. An LSP selling pharmaceutical products must also prominently display at the premises, in English and Chinese, a notice stating that antibiotics must not be sold there. Names, emblems, descriptions or symbols that imply the sale of medicines beyond the permitted scope, that the premises is an ASP, or that a registered pharmacist supervises it must not be used inside or outside the shop.

[Risk alert] The Code requires Part II poisons to be sold by retail only at the premises specified in the licence. Accordingly, do not assume that the existing licence automatically covers relocation, an additional sales outlet, use of a back room as a retail point, or an online ordering arrangement extending to another actual stock or delivery location. Confirm the case-specific arrangements for a change of premises, inspection or register amendment with the Drug Office before signing, fitting out or opening.

Day-to-day LSP compliance is not just about whether medicines are on the shelves. For every batch, the business must be able to account for its source, registration, packaging, batch number, expiry date, storage status and destination.

[Official Code requirements] The premises must have a storeroom or designated storage facilities so that pharmaceutical products can be stored in an orderly manner. Medicines must be stored under appropriate conditions, away from food, and in the manufacturer’s original packaging. The outer packaging of all pharmaceutical products for sale must clearly show the batch number and expiry date. Products may only be sold or supplied in the original, unopened containers provided by the manufacturer. Breaking packs, relabelling, mixing products or obscuring batch numbers or expiry dates undermines traceability.

[Statutory / Code controls] The licence holder must establish procedures to prevent the supply of expired stock to the public, check expiry dates regularly and remove all expired products from sales and display areas for appropriate disposal or destruction. Upon receiving genuine recall information and notification from a manufacturer, wholesaler or the Department of Health, the licence holder must actively participate in the recall and immediately remove the recalled products from stock to prevent further distribution.

[Specific retention period] On receipt, check the product name, quantity, batch number and expiry date against the sales invoice, purchase order or delivery note. The Code requires these sales invoices, purchase orders or delivery notes to be retained for inspection for 2 years from the date of issue or until the relevant pharmaceutical product expires, whichever is longer. This 2-year rule applies to these transaction documents. Do not extend it to all LSP records or apply record retention periods for other types of licence to an LSP.

Product registration and LSP retail eligibility must both be in place, but they are not the same licence. Procurement, wholesale, import and export should also be distinguished according to the actual role in each transaction.

【Official Code】An LSP must ensure that the pharmaceutical products it supplies are Hong Kong-registered products obtained from licensed medicine dealers, and exercise reasonable diligence to avoid supplying counterfeit or unregistered products, or products adulterated with undeclared Western medicines. The Code also requires that, before purchasing, the seller must not buy products whose quality, safety, efficacy and authenticity cannot be verified. A “Hong Kong registration number” is therefore only one part of the verification; it does not remove the LSP’s responsibility for restrictions on sales categories, sources and premises.

【Regulatory interface】The Drug Office states that, in principle, pharmaceutical products should be registered with the Board before being sold or distributed in Hong Kong. However, retail locations and conditions differ for Part II poisons, non-poisons and Part I poisons. If an operator actually engages in the wholesale, import or export of pharmaceutical products or poisons, the corresponding regime listed in the FAQ is the Wholesale Dealer Licence; imports and exports are also subject to licensing controls under the Import and Export Ordinance. An LSP procuring retail stock from compliant suppliers should not be described as thereby automatically having wholesale or import/export eligibility.

【SKU release recommendation】Before first procurement, engaging a new supplier, changing packaging or changing product registration, check in sequence the supplier’s eligibility, registration and labelling details, the boundaries for Part II poisons, whether antibiotics or dangerous drugs are involved, applicable advertising restrictions, and storage conditions at the approved premises. If any item cannot be verified, the product should not be placed in saleable stock.

A complete application should show consistency between the entity, personnel, premises and proposed sales activity. Official forms are essential submissions; self-prepared procedures and photographs may serve only as supporting material and cannot replace statutory declarations.

【Official requirements】Use the LSP application form and checklist version current at the time of submission, together with the application fee, Business Registration proof and documents required for the relevant entity type. The checklist also requires details of the proprietor/partners/directors and all Western medicine staff, declarations from all relevant persons, and a statement on the appointment of Western medicine staff signed by the proprietor, a partner or a director. Insufficient information may prevent the Department of Health from assessing eligibility or the suitability of the persons concerned.

【Scope of declarations】Personal declarations cover whether, during the past three years, the person has been a proprietor, director or employee of another Western medicine trader, and whether they are currently under investigation or prosecution, or have had a drug-related conviction. A limited company must also make the corresponding declaration where applicable. All information should be verified and signed by the persons actually concerned. A consultant may help organise evidence and check consistency, but cannot make factual declarations on behalf of the applicant or staff.

【Drew Tang’s practical advice】Organise the documents into five folders: “official forms and fees”, “entity documents”, “personnel declarations”, “evidence for premises inspection”, and “product and supply-chain controls”. Mark each document with its version, signatory, date and corresponding application field. Keep submission copies, proof of payment and all subsequent correspondence about supplementary documents in a single file for traceability during renewal, transaction due diligence and inspections.

The process runs from document review to premises inspection, any necessary supplementary submissions, consideration by the committee and, if approved, commencement of business. Treat the site inspection as a verification of actual operating capability that can be demonstrated, not merely as an acceptance inspection of renovation works.

【Official procedure】After the completed application, required documents and fee have been submitted, the Department of Health will issue an acknowledgement of receipt of the application fee. The application guidance states that, upon receipt of a complete application, the premises will be inspected for suitability for retailing Part II poisons, and all applications will be submitted to the relevant committee of the Board for consideration. The Listed Sellers of Poisons Committee under the Board is established under regulation 24A of Cap. 138A to consider and approve LSP applications. Filing an application does not itself authorise business operations.

【Inspection preparation】The application guidance gives examples of storage conditions for the first inspection, while the Code also requires storage facilities, appropriate storage, batch numbers and expiry dates, display of the licence, an antibiotics notice and a compliant name. The responsible person should be able to explain where goods are received, how saleable and quarantined stock are distinguished, how products and suppliers are verified, who is authorised to release goods, and how expired or recalled goods are handled. Current materials do not describe LSP site questions as a uniform statutory “interview”, so they should not be promoted as a compulsory examination.

【Supplementary submission control】One person should coordinate regulatory enquiries, recording each question, the related material in the original application, accurate updated information and the submission date. If a supplementary submission reflects a material change to the entity, personnel, premises or business scope, first confirm whether a correction, application amendment or re-inspection is required; do not use an informal verbal explanation as a substitute for formal documents.

Fees and time should be separated into prescribed government fees, actual third-party costs, internal operating costs and consultancy service fees. Bundling these as a “licence package” obscures renewal risks and approval conditions.

【Current official figures】The current LSP checklist and application guidance specify a first application fee of HK$455, which is non-refundable, and an annual retention fee of HK$430. Fees may be adjusted by law or when forms are updated. At the time of engagement, quotation and submission, use the official forms, payment methods and prescribed fees then in force, rather than figures from an old webpage or a consultant’s quotation.

【Time-limit context】The application guidance states that, if approved, a licence issued under section 25 expires on 31 December of the same year in which it is approved. The Department of Health’s two-month performance pledge is subject to express conditions: the premises are suitable, the applicant and key personnel have clean criminal and disciplinary records, and the first inspection is satisfactory. The two months should therefore be understood as a conditional performance pledge, not a guaranteed approval date for every application.

【Drew Tang’s practical advice】Divide the budget across four stages: preparation of the entity and premises before filing; remediation and equipment before approval; the first compliant stock order before commencement of business; and annual renewal and ongoing controls. List government fees, Business Registration or company documents, rent and renovation, storage equipment, stock, insurance, staff and consultancy fees separately. Consultancy fees are service charges and must not be described as government fees.

The Code sets out ongoing outcome requirements, such as regular expiry-date checks, immediate removal of recalled products, retention of transaction documents and cooperation with inspections. Businesses can use these to design practical daily and periodic controls.

【Daily controls】For each delivery, check the product name, quantity, batch number and expiry date against the invoice, purchase order or delivery note. Also confirm consistency between the product’s original packaging, registration details, supplier and conclusions in the SKU master file. Expired, damaged, unverified-source, recalled, incorrectly delivered or prohibited-category goods must not enter the saleable area; quarantine them first and have the responsible person deal with them.

【Periodic controls】The Code requires regular expiry-date checks and removal of expired products from sales and display areas. Upon receipt of a genuine recall notice, products must be removed from stock immediately. As the Code does not prescribe a uniform daily, weekly, monthly or quarterly frequency for LSPs, set the internal stocktaking calendar according to stock volume, expiry dates, cold-chain or other actual risks, and make clear that it is an operational control, not an officially specified frequency.

【Inspection cooperation】Licensees must cooperate with Department of Health inspectors and, upon reasonable request, provide information relating to licensed activities or staff at the premises. Keep the licence, trade-name display, antibiotics notice, staff list, purchase documents, expiry/exception/recall records and current stock status ready. If a discrepancy is found during a regulatory visit, record it accurately, quarantine the item at risk and make corrections as required.

Renewal and change management should be prepared throughout the licence validity period, not left until the expiry date or after a transaction has completed.

【Annual maintenance】Section 25 of Cap. 138 requires persons remaining on the LSP register to pay the prescribed annual fee; the Code also requires persons seeking renewal to pay annually. The current application guidance states that a new licence issued under section 25 expires on 31 December of the year in which it is approved. Before renewal, check that the approved entity, premises, licence display, personnel, stock, suppliers, records and remediation status remain accurate; paying the fee alone is not enough.

【Matters expressly requiring prior approval】The Code requires prior Board approval for any change to a sole proprietor, partnership or directors. Without prior approval, a licensee may be removed from the register and the licence may cease to be valid from the date of removal. Section 25 of Cap. 138 also permits an application to the Board for approval of changes to register particulars. In practice, determine the specific forms, documents, fees, inspections and timing before the change takes effect.

【Matters not uniformly specified】The LSP materials verified do not provide a separate relocation form or fixed relocation-notification deadline, nor do they state a general rule that ordinary shareholder changes are treated exactly like director changes. Therefore, do not describe relocation as a routine filing, or assert categorically that no shareholding change affects a licence. For a new address, shareholding, actual management, responsible person, trade name or material change in publicity, it is safer to confirm the case-specific process with the Drug Office first.

An LSP transaction concerns more than a “licensed company”. The buyer must also verify register eligibility, the licensee, approved premises, key personnel, stock and ongoing records, and ensure the transaction structure matches the sole proprietorship, partnership or company form.

【Characterising the transaction】First confirm whether the licence holder is a sole proprietorship, partnership or limited company. Then identify whether the proposed transfer of assets, business transfer, adjustment of partnership interests or company share transaction would change the proprietor, partnership, directors, actual management or approved premises. The Code requires prior approval for changes to the proprietor, partnership or directors. No acquisition structure should therefore be promoted as automatically carrying over the licence, nor should a 100% share acquisition be described as the only option.

【Seller due diligence checklist】Check the LSP licence and expiry date, register particulars, approved entity and premises, correspondence with the Board/Drug Office, renewal and remediation status, personnel declarations, shop signs and advertising, supplier eligibility, SKU classification, product registration, stock batch numbers and expiry dates, purchase and delivery documents, expired/recalled/quarantined goods and tenancy. Verbal assurances about medicine categories, premises or personnel are no substitute for original documents.

【Completion controls】Make any required Board approval or written confirmation, premises arrangements, personnel changes, handling of prohibited stock and handover of licence information conditions precedent to the transaction or post-completion restrictions. On the completion date, acknowledge receipt item by item of the licence and regulatory documents, stocktake, keys and system access, supplier information, staff responsibilities, recall and exception records, shop signs and online pages, and the next renewal date. Until any required approval or confirmation is obtained, the buyer should not purport to operate as an LSP under a new management team or entity.